WO2002040702A3 - Methods for the treatment of cancer and other diseases and methods of developing the same - Google Patents
Methods for the treatment of cancer and other diseases and methods of developing the same Download PDFInfo
- Publication number
- WO2002040702A3 WO2002040702A3 PCT/US2001/046194 US0146194W WO0240702A3 WO 2002040702 A3 WO2002040702 A3 WO 2002040702A3 US 0146194 W US0146194 W US 0146194W WO 0240702 A3 WO0240702 A3 WO 0240702A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- cancer
- diseases
- treatment
- developing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002239491A AU2002239491A1 (en) | 2000-11-09 | 2001-11-08 | Methods for the treatment of cancer and other diseases and methods of developing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24671700P | 2000-11-09 | 2000-11-09 | |
US60/246,717 | 2000-11-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002040702A2 WO2002040702A2 (en) | 2002-05-23 |
WO2002040702A3 true WO2002040702A3 (en) | 2004-01-08 |
Family
ID=22931903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/046194 WO2002040702A2 (en) | 2000-11-09 | 2001-11-08 | Methods for the treatment of cancer and other diseases and methods of developing the same |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002239491A1 (en) |
WO (1) | WO2002040702A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8834913B2 (en) | 2008-12-26 | 2014-09-16 | Battelle Memorial Institute | Medical implants and methods of making medical implants |
US8852625B2 (en) | 2006-04-26 | 2014-10-07 | Micell Technologies, Inc. | Coatings containing multiple drugs |
US8900651B2 (en) | 2007-05-25 | 2014-12-02 | Micell Technologies, Inc. | Polymer films for medical device coating |
US9433516B2 (en) | 2007-04-17 | 2016-09-06 | Micell Technologies, Inc. | Stents having controlled elution |
US9486431B2 (en) | 2008-07-17 | 2016-11-08 | Micell Technologies, Inc. | Drug delivery medical device |
US9510856B2 (en) | 2008-07-17 | 2016-12-06 | Micell Technologies, Inc. | Drug delivery medical device |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090062909A1 (en) | 2005-07-15 | 2009-03-05 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
AU2006270221B2 (en) | 2005-07-15 | 2012-01-19 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
US9539593B2 (en) | 2006-10-23 | 2017-01-10 | Micell Technologies, Inc. | Holder for electrically charging a substrate during coating |
US9737642B2 (en) | 2007-01-08 | 2017-08-22 | Micell Technologies, Inc. | Stents having biodegradable layers |
US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
CA2721832C (en) | 2008-04-17 | 2018-08-07 | Micell Technologies, Inc. | Stents having bioabsorbable layers |
US20100239635A1 (en) | 2009-03-23 | 2010-09-23 | Micell Technologies, Inc. | Drug delivery medical device |
CN102481195B (en) | 2009-04-01 | 2015-03-25 | 米歇尔技术公司 | Drug delivery medical device |
WO2011097103A1 (en) | 2010-02-02 | 2011-08-11 | Micell Technologies, Inc. | Stent and stent delivery system with improved deliverability |
US8795762B2 (en) | 2010-03-26 | 2014-08-05 | Battelle Memorial Institute | System and method for enhanced electrostatic deposition and surface coatings |
BR112012024619A2 (en) * | 2010-03-31 | 2016-05-31 | Diatech Oncology Llc | system and method for evaluating anticancer drug candidate |
WO2011133655A1 (en) | 2010-04-22 | 2011-10-27 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
CA2805631C (en) | 2010-07-16 | 2018-07-31 | Micell Technologies, Inc. | Drug delivery medical device |
WO2012166819A1 (en) | 2011-05-31 | 2012-12-06 | Micell Technologies, Inc. | System and process for formation of a time-released, drug-eluting transferable coating |
US10117972B2 (en) | 2011-07-15 | 2018-11-06 | Micell Technologies, Inc. | Drug delivery medical device |
US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
US9476871B2 (en) * | 2012-05-02 | 2016-10-25 | Diatech Oncology Llc | System and method for automated determination of the relative effectiveness of anti-cancer drug candidates |
JP2015517662A (en) * | 2012-05-15 | 2015-06-22 | ダイアテツク・オンコロジー | Tumor cell isolation / purification method and method of use thereof |
AU2014248508B2 (en) | 2013-03-12 | 2018-11-08 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
JP2016519965A (en) | 2013-05-15 | 2016-07-11 | マイセル・テクノロジーズ,インコーポレイテッド | Bioabsorbable biomedical implant |
WO2015171848A2 (en) * | 2014-05-08 | 2015-11-12 | Diatech Oncology, Llc | Synergism and antagonism between multiple anti-cancer agents determined by mick assay |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994017177A1 (en) * | 1993-01-27 | 1994-08-04 | Batle Luminetrics Enterprises, Inc. | Methods and kits for determining effects of anti-cancer agents on cancer cells |
US6077684A (en) * | 1996-11-14 | 2000-06-20 | Vanderbilt University | Automated assay for measuring apoptosis in cell culture |
-
2001
- 2001-11-08 WO PCT/US2001/046194 patent/WO2002040702A2/en not_active Application Discontinuation
- 2001-11-08 AU AU2002239491A patent/AU2002239491A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994017177A1 (en) * | 1993-01-27 | 1994-08-04 | Batle Luminetrics Enterprises, Inc. | Methods and kits for determining effects of anti-cancer agents on cancer cells |
US6077684A (en) * | 1996-11-14 | 2000-06-20 | Vanderbilt University | Automated assay for measuring apoptosis in cell culture |
Non-Patent Citations (1)
Title |
---|
KRAVTSOV V.D. ET AL.: "Use of the microculture kinetic assay of apoptosis to determine chemosensitivities of leukemias.", BLOOD, vol. 92, no. 3, 1 August 1998 (1998-08-01), pages 968 - 980, XP002118802 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8852625B2 (en) | 2006-04-26 | 2014-10-07 | Micell Technologies, Inc. | Coatings containing multiple drugs |
US9415142B2 (en) | 2006-04-26 | 2016-08-16 | Micell Technologies, Inc. | Coatings containing multiple drugs |
US11850333B2 (en) | 2006-04-26 | 2023-12-26 | Micell Medtech Inc. | Coatings containing multiple drugs |
US9433516B2 (en) | 2007-04-17 | 2016-09-06 | Micell Technologies, Inc. | Stents having controlled elution |
US9486338B2 (en) | 2007-04-17 | 2016-11-08 | Micell Technologies, Inc. | Stents having controlled elution |
US8900651B2 (en) | 2007-05-25 | 2014-12-02 | Micell Technologies, Inc. | Polymer films for medical device coating |
US9486431B2 (en) | 2008-07-17 | 2016-11-08 | Micell Technologies, Inc. | Drug delivery medical device |
US9510856B2 (en) | 2008-07-17 | 2016-12-06 | Micell Technologies, Inc. | Drug delivery medical device |
US8834913B2 (en) | 2008-12-26 | 2014-09-16 | Battelle Memorial Institute | Medical implants and methods of making medical implants |
Also Published As
Publication number | Publication date |
---|---|
AU2002239491A1 (en) | 2002-05-27 |
WO2002040702A2 (en) | 2002-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002040702A3 (en) | Methods for the treatment of cancer and other diseases and methods of developing the same | |
WO2005055944A3 (en) | Oligosaccharide compositions and use thereof in the treatment of infection | |
WO2004006858A3 (en) | Compounds, compositions, and methods employing same | |
WO2005084296A3 (en) | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogernase 3 | |
WO2004113275A3 (en) | Methods and compositions for treating amyloid-related diseases | |
IL173348A (en) | Thienopyridine compounds, pharmaceutical compositions comprising same and use thereof in the preparation of medicaments | |
WO2003030934A3 (en) | Cpg formulations and related methods | |
AU2002305450A1 (en) | Proteomimetic compounds and methods | |
WO2008039218A3 (en) | Inhibitors of bruton's tyrosine kinase | |
NO20053855D0 (en) | 1-Phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases. | |
IL157656A (en) | Metalloproteinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of diseases mediated by metalloproteinase enzymes | |
AU2003225800A1 (en) | Azolylaminoazine as inhibitors of protein kinases | |
AU2003220299A1 (en) | Azinylaminoazoles as inhibitors of protein kinases | |
AU2003218215A1 (en) | Azolylaminoazines as inhibitors of protein kinases | |
AU2003220300A1 (en) | Compositions useful as inhibitors of protein kinases | |
AU2002248384A1 (en) | Serpin drugs for treatment of hiv infection and method of use thereof | |
PL1654253T3 (en) | Substituted 3-pyrrolidin-indole derivatives | |
WO2004071382A3 (en) | Substituted heterocycles | |
IL171974A0 (en) | Tetrahydrocarbazole derivatives and their pharmaceutical use | |
WO2007002836A3 (en) | Methods and compositions for the prevention and treatment of kidney disease | |
AU2001235006A1 (en) | Prophylactic and therapeutic monoclonal antibodies | |
IS6558A (en) | Mixed disease treatment with vasoconstrictor | |
WO2004073615A8 (en) | Deazaflavin compounds and methods of use thereof | |
WO2003017939A3 (en) | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment | |
WO2002067771A3 (en) | Chemokine receptors and disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |